Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ACELYRIN, INC. - Common Stock (NQ:SLRN)

2.580 -0.160 (-5.84%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about ACELYRIN, INC. - Common Stock

< Previous 1 2 3 Next >
Top 5 Biotech Stocks That Saw Biggest Retail Following Jump Last Week
Investors on Stocktwits flocked to these five biotech stocks last week, ending Feb. 21, 2025, driven by buyout buzz, bullish analyst calls, and promising clinical developments. 
Via Stocktwits
These stocks are moving in today's pre-market session
As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
Wondering what's happening in today's after-hours session?
As the regular session of the US market on Thursday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill
Nasdaq Down 1.5%; RPM Posts Upbeat Results
Via Benzinga
Earnings Scheduled For November 13, 2024
Via Benzinga
Earnings Preview: Acelyrin
Via Benzinga
SLRN Stock Earnings: Acelyrin Misses EPS for Q2 2024
SLRN stock results show that Acelyrin missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
SLRN Stock Earnings: Acelyrin Beats EPS for Q1 2024
SLRN stock results show that Acelyrin beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Dow Surges Over 100 Points; US Trade Deficit Widens In November
Via Benzinga
Topics Stocks
Exposures US Equities
Acelyrin, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Why Inari Medical Shares Are Trading Higher By 21%; Here Are 20 Stocks Moving Premarket
Via Benzinga
What's Going On With ACELYRIN Shares Friday?
ACELYRIN shares are moving higher on Friday after the company announced that it will reveal Phase 2 data and announce Phase 3 plans for Subcutaneous Lonigutamab at a virtual investor event. 
Via Benzinga
Rivian Automotive, Cerence, Nu Skin Enterprises And Other Big Stocks Moving Higher On Friday
Via Benzinga
SLRN Stock Earnings: Acelyrin Beats EPS for Q4 2023
SLRN stock results show that Acelyrin beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
What 5 Analyst Ratings Have To Say About Acelyrin
Via Benzinga
Macy's, Dave & Buster's, Bausch + Lomb And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Fabrinet Posts Strong Earnings, Joins Amer Sports, Hawaiian Holdings And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Acelyrin Cuts Workforce, Deprioritizes Former Lead Drug Izokibep
Acelyrin reports promising Phase 3 results for izokibep in hidradenitis suppurativa, announces a strategic focus on lonigutamab. 
Via Benzinga
Ouster Reports Weak Sales, Joins Brinker International And Other Big Stocks Moving Lower In Wednesday Pre-Market Session
Via Benzinga
Why Arhaus Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Investors Cheer Acelyrin's Stock, Its Second Lead Candidate Shows Clinical Benefit In Thyroid Eye Disease Patients
Acelyrin releases Phase 1/2 trial results of lonigutamab. Rapid improvements in eye bulge and double vision. Well-tolerated with no serious adverse events. Phase 2b/3 trial slated for the second half... 
Via Benzinga
Acelyrin's Lead Drug Candidate Hits Primary Goal In Late-Stage Psoriatic Arthritis Study
Acelyrin reports positive Phase 2b/3 trial results for izokibep in psoriatic arthritis, achieving ACR50 at week 16 with high statistical significance. Long-term data in hidradenitis suppurativa show... 
Via Benzinga
Are November’s 3 Biggest Stock Losers Worth Snapping Up Now?
The market was like an iceberg with only a few winners showing but that means there are a lot of the biggest stock losers worth getting now. 
Via InvestorPlace
Why SenesTech Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of SenesTech, Inc. (NASDAQ: SNES) shares moved lower during Tuesday’s session after the company reported pricing of $5.0 million public offering. 
Via Benzinga
Why Is Inflammation Disease Focused Acelyrin Stock Trading Lower Today?
Acelyrin Inc (NASDAQ: SLRN) updated its izokibep clinical development program, including its ongoing global Phase 2b/3 trial for izokibep in  
Via Benzinga
Acelyrin (SLRN) Q3 2023 Earnings Call Transcript
SLRN earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Moonshot Medicine: 3 Stocks to Buy to Bet on Long-Shot Drugs
The best drug stocks to buy now are shooting for the moon. These three trailblazers will land among the stars. 
Via InvestorPlace
Stocks That Hit 52-Week Lows On Thursday
  During the session on Thursday, 461 stocks hit new 52-week lows. 
Via Benzinga
Earnings Scheduled For November 7, 2023
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter. 
Via Benzinga
Why Acelyrin Stock Plummeted 59% This Week
The recently public biopharma company announced disappointing results from a clinical trial of its lead drug candidate. 
Via The Motley Fool
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS